Pharma M&A Is all about Options

The days of mega-mergers in the pharmaceutical sector aren’t necessarily over, but those deals will be fewer and farther between, going forward. Nearly 60 deals have been announced in 2016 through the middle of May, and just 17 have an entire company as the target. The largest, so far, is Shire‘s (NASDAQ: SHPG) $32 billion […]

AbbVie Gets Ahead of the Bad News Curve

On March 11, Sanofi (NYSE: SNY)  and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that an experimental rheumatoid arthritis therapy (salrilumab) helped patients more than AbbVie Inc.’s (NYSE: ABBV) Humira in a late-stage trial. But AbbVie already had a new deal in place, a collaboration with Boehringer Ingelheim, that was announced on March 7. Under terms of the agreement, AbbVie […]

Hanmi Pharmaceutical Deals with Sanofi, Janssen

Korean pharmaceutical company Hanmi Pharmaceutical Co., Ltd. popped up on the healthcare M&A radar last week with two collaboration announcements. First was an agreement with French drug maker Sanofi (NYSE: SNY) to grant the worldwide license to a yet-to-be developed portfolio of experimental, long-acting diabetes treatments. Sanofi paid an upfront fee of €400 million ($434,820,000) and is […]